Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2026Journal of Crohn s and Colitis

OP27Integrative single-cell, spatial, and clinical analysis supports JAK1 inhibition as a compelling therapeutic strategy in perianal Crohn’s disease

View Full Paper
Ask AI
Bookmark
Share

Authors

LHL HannaASAamir SaifuddinDCDomenico Cozzetto

Discussion

Loading...

Member takes

Overview

Integrative analysis supports JAK1 inhibition improves outcomes in perianal Crohn's disease, suggesting new therapy avenues.

Key Points

  • This research aims to evaluate the efficacy of JAK1 inhibition in treating perianal Crohn’s disease (pCD).
  • Single-cell RNA sequencing was performed on immune cells from fistula samples of 12 pCD patients.
  • Immunohistochemistry was utilized to assess JAK1 activity in tissue specimens.
  • A case series reviewed clinical outcomes of 20 pCD patients treated with upadacitinib.
  • Single-cell RNA sequencing identified 18 immune cell populations with enriched interferon-γ responses in pCD.
  • JAK1 inhibition with upadacitinib decreased interferon-related gene expression.
  • Clinical remission was achieved in 45% of patients, with 58% showing radiological response.

Cite This Study

Hanna et al. (2026) studied this question.

synapsesocial.com/papers/69730f78c8125b09b0d1f42chttps://doi.org/10.1093/ecco-jcc/jjaf231.027
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1DOP076 Spatially and functionally uncoupled cytokine responses differentially activate wound healing and keratinisation responses in a prognostically relevant manner in perianal fistulising Crohn’s disease2026
  2. 2P0785 One-Year Efficacy of Upadacitinib in Perianal Crohn’s Disease: A Multicenter Cohort Study.2026
  3. 3P0345 What are the Top 10 Global Research Priorities for Perianal Crohn’s disease? The Global Perianal Crohn’s disease Priority Setting Partnership2026
  4. 4P0500 Outcome Heterogeneity in Perianal Fistulising Crohn’s Disease: A Systematic Review for the TOpClass Treat-to-Target Initiative2026
  5. 5P0350 ECCO Global Grant 2025: determining transethnic, transcontinental differences in perianal fistulising Crohn’s disease2026